Trial Profile

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ethyl eicosapentaenoic acid (Primary)
Indications COVID 2019 infections; Respiratory tract infections
Focus First in man; Pharmacodynamics
Acronyms CardioLink-9

Most Recent Events

07 Jan 2021 Status changed from recruiting to completed, according to an Amarin Corporation media release.
14 Dec 2020 According to a Canadian Medical and Surgical group media release, the study has been approved by Health Canada.
14 Dec 2020 Results presented in a Canadian Medical and Surgical group media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com